James Archie Harrell Jr
CIK 1738462 · Chief Commercial Officer · last filed 2021-12-14
James Archie Harrell Jr is a Chief Commercial Officer who has filed 11 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing shows the insider bought $1.7K of AVTX on Dec 14, 2021. Across all open-market trades the lifetime net is +$91.8K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $88 across reported positions. 12 SEC filings were submitted jointly with Cerecor Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CERC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
400 E. PRATT STREET, SUITE 606
BALTIMORE, MD 21202
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVTX | Chief Commercial Officer | 13 | $6.77 | $88 | $1.7K | 1 | 2021-12-14 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Chief Commercial Officer | 35,673 | $2.93 | $104.5K | $90.1K | 9 | 2021-06-14 |
| Avalo Therapeutics, Inc. (CERCW) Delisted | Exec. VP, Mktg & External Comm | — | — | — | $0 | 1 | 2018-05-08 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-12-14 | AVTX | Buy (P) | +1,093 | $1.7K | EDGAR |
| 2021-06-14 | Avalo Therapeutics, Inc. (CERC) Delisted | Buy (P) | +7,493 | $17.1K | EDGAR |
| 2021-01-28 | Avalo Therapeutics, Inc. (CERC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-12-14 | Avalo Therapeutics, Inc. (CERC) Delisted | Buy (P) | +171 | $390 | EDGAR |
| 2020-06-11 | Avalo Therapeutics, Inc. (CERC) Delisted | Buy (P) | +16,391 | $39.6K | EDGAR |
| 2020-04-13 | Avalo Therapeutics, Inc. (CERC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-12-11 | Avalo Therapeutics, Inc. (CERC) Delisted | Buy (P) | +3,064 | $8.7K | EDGAR |
| 2019-06-11 | Avalo Therapeutics, Inc. (CERC) Delisted | Buy (P) | +4,398 | $12.5K | EDGAR |
| 2019-04-02 | Avalo Therapeutics, Inc. (CERC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-12-11 | Avalo Therapeutics, Inc. (CERC) Delisted | Buy (P) | +4,156 | $11.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.